(AWP) The Novartis subsidiary Sandoz strengthens its portfolio for the treatment of respiratory diseases. For this purpose, the British Coalesce Product Development was taken over, the generics division announced on Monday. The British company specializes in the development of medical devices and drugs.
This expands the existing portfolio of respiratory drugs, the statement continues. No information was given on the takeover price or the size of Coalesce in the announcement.
With a portfolio of six products already on the market and almost twice as many products in the pipeline, Sandoz sees the area of respiratory diseases as one of the most important pillars for the long-term growth strategy.
–
